No profile data available.
Mustang Bio, Inc. (MBIO) is a healthcare company in the additional cancer treatment drugs industry, based in Waltham, United States, with about 4 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$1.92 million. In Q1 2026 (the quarter ended March 31, 2026) revenue was $0. Its market capitalization was $3.03 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States.
Mustang Bio reported $0 in revenue for fiscal year 2025. In Q1 2026 revenue was $0.
$3.03 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Calidi Biotherapeutics, Inc. (CLDI), Indaptus Therapeutics, Inc. (INDP), Silexion Therapeutics Corp (SLXN), Kairos Pharma, Ltd. (KAPA).